Cargando…
Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246
Although a large number of compounds have been identified with antiviral activity against orthopoxviruses in tissue culture systems, it is highly preferred that these compounds have activity in vivo before they can be seriously considered for further development. One of the most commonly used animal...
Autores principales: | Quenelle, Debra C., Kern, Earl R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185598/ https://www.ncbi.nlm.nih.gov/pubmed/21994637 http://dx.doi.org/10.3390/v2122681 |
Ejemplares similares
-
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir
por: Quenelle, Debra C, et al.
Publicado: (2004) -
Development of CMX001 for the Treatment of Poxvirus Infections
por: Lanier, Randall, et al.
Publicado: (2010) -
Isolation and characterization of cidofovir resistant vaccinia viruses
por: Becker, Marie N, et al.
Publicado: (2008) -
Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient
por: Sudhindra, Praveen, et al.
Publicado: (2019) -
Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA
por: Lorenzo, María M., et al.
Publicado: (2017)